NCT03268369

Brief Summary

Mutations in neuronal nicotinic acetylcholine receptors (nAChRs) have been identified in the autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Despite the demonstration of a gain of function of the mutated receptors, the precise mechanisms leading to this nocturnal epilepsy are still unknown. In 2006 the investigators studied the nAChR cerebral distribution in a group of patients with ADNFLE carrying a nAChR mutation, by a PET-scan using \[18F\]-F-A-85380, a ligand with a high affinity and specificity for alpha4beta2 nicotinic receptors. The study showed a different pattern of brain distribution of the radiotracer in the ADNFLE patients when compared to a group of control subjects, with a significant increase of nicotinic receptor density in the patients in mesencephalon and cerebellum (Picard et al., Brain 2006). Based on the known biochemical and cellular circuits in the brainstem, these results suggest that the nAChR density increase in mesencephalon is involved in the pathophysiology of ADNFLE through the role of brainstem ascending cholinergic systems in arousal. The follow-up step consists of extending this examination to other forms of epilepsy, in order to verify the specificity of the hyperfixation pattern for ADNFLE, and search for a potential involvement of nicotinic receptors in other forms of epilepsy. The investigators aim to study 5 groups of subjects: control subjects (Group 1, 20 subjects); patients with a non lesional partial epilepsy and a predominance of diurnal seizures (Group 2, 12 subjects); patients with an idiopathic generalized epilepsy (Group 3, 12 subjects); patients with nocturnal frontal lobe epilepsy (Group 4, 3 subjects) and epileptic patients with vagal nerve stimulation (Group 5, 1 subject). For each patient, a cerebral MRI, \[18F\]- fluorodeoxyglucose (FDG) PET/CT and \[18F\]-F-A-85380 PET/CT examinations are planned. The investigators will perform data analyses on volume of distribution (Vt) parametric images which will be based on the ratio of brain tissue to unchanged F-A-85380 plasma at equilibrium. Statistical parametric mapping (SPM2) will be used to further study the parametric PET images. This study is primarily dedicated to demonstrate that the pattern of hyperfixation that was obtained in ADNFLE patients is specific for this disorder and does not constitute a common pattern to various forms of epilepsy. The investigators will also search for a possible involvement of the nAChRs in other forms of epilepsy.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2012

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2012

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2015

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

August 24, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 31, 2017

Completed
Last Updated

August 31, 2017

Status Verified

August 1, 2017

Enrollment Period

3.8 years

First QC Date

August 24, 2017

Last Update Submit

August 30, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Comparison of the cerebral distribution of the neuronal nicotinic acetylcholine receptors (nAChR) in the 5 groups of individuals by means of voxelwise and regional 18F-FA binding potential measurements

    Parametric 18F-FA and 18F-FDG binding potential measurements will be compared between the different groups of patients with epilepsy and the control group in order to find specific changes in the cerebral distribution of the nicotinic receptors in the different types of epilepsy, by using a voxel-wise (SPM) and a volume of interest (VOI) analysis.

    1 month

Study Arms (5)

Control group

ACTIVE COMPARATOR
Radiation: MRI of the brainRadiation: PET scan [18F]F-A-85380Radiation: PET scan [18F]FDG

Non lesional diurnal partial epilepsy

EXPERIMENTAL
Radiation: MRI of the brainRadiation: PET scan [18F]F-A-85380Radiation: PET scan [18F]FDG

Idiopathic generalized epilepsy

EXPERIMENTAL
Radiation: MRI of the brainRadiation: PET scan [18F]F-A-85380Radiation: PET scan [18F]FDG

Nocturnal frontal lobe epilepsy

EXPERIMENTAL
Radiation: MRI of the brainRadiation: PET scan [18F]F-A-85380Radiation: PET scan [18F]FDG

Epileptic patients with Vagus Nerve Stimulation (VNS)

EXPERIMENTAL
Radiation: PET scan [18F]F-A-85380Radiation: PET scan [18F]FDG

Interventions

to eliminate a structural intra-cerebral lesion

Control groupIdiopathic generalized epilepsyNocturnal frontal lobe epilepsyNon lesional diurnal partial epilepsy

exam performed after iv injection of 200 MBq \[18F\]F-A-85380

Control groupEpileptic patients with Vagus Nerve Stimulation (VNS)Idiopathic generalized epilepsyNocturnal frontal lobe epilepsyNon lesional diurnal partial epilepsy

exam performed after iv injection of 200 MBq \[18F\]FDG

Control groupEpileptic patients with Vagus Nerve Stimulation (VNS)Idiopathic generalized epilepsyNocturnal frontal lobe epilepsyNon lesional diurnal partial epilepsy

Eligibility Criteria

Age18 Years - 60 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • males
  • years old
  • non-smokers

You may not qualify if:

  • smoking during the past twelve months
  • contraindications to MRI
  • brain lesions on MRI (including hippocampal atrophy)
  • neurological disorder (other than epilepsy) or psychiatric disorder
  • neoplasia or coronary disease
  • blood test showing : creatinine clearance \< 50 ml/min, or platelet \< 100 G/l, or leucocytes \< 3.8 G/l, or ALT or AST \> 2 x upper standard, or gamma-GT \> 3 x upper standard, or albumin \< 35 g/l or \> 48 g/l .
  • patients only : nuclear imaging during the past twelve months
  • healthy volunteers only : ionising radiation exam during the past five years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Picard F, Bruel D, Servent D, Saba W, Fruchart-Gaillard C, Schollhorn-Peyronneau MA, Roumenov D, Brodtkorb E, Zuberi S, Gambardella A, Steinborn B, Hufnagel A, Valette H, Bottlaender M. Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Brain. 2006 Aug;129(Pt 8):2047-60. doi: 10.1093/brain/awl156. Epub 2006 Jun 30.

    PMID: 16815873BACKGROUND

MeSH Terms

Conditions

Epilepsy

Interventions

Magnetic Resonance SpectroscopyFluorodeoxyglucose F18

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative TechniquesDeoxyglucoseDeoxy SugarsCarbohydrates

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Doctor, University Hospital, Geneva

Study Record Dates

First Submitted

August 24, 2017

First Posted

August 31, 2017

Study Start

February 1, 2012

Primary Completion

November 1, 2015

Study Completion

November 1, 2015

Last Updated

August 31, 2017

Record last verified: 2017-08